manufactur pressur distribut solid growth
commun tasli manag recent tasli still
solid growth manufactur distribut segment
diversifi futur pipelin cardiovascular oncolog
diabet therapi support long-term growth
ke sale went yoy mn
includ ndrl tasli expect drug sale reach
mn distribut sale grew gm
improv pp yoy continu trend
despit solid growth think tasli tcm portofolio face
pressur supplement drug control restrict tcm
inject compani focus develop new
biolog drug diversifi portfolio
maintain neutral tcm inject draw sale
growth short term cut ep view tcm
inject remain pressur lift dcf-base tp
factor rich pipelin
drive long-term growth also introduc forecast
estimate pot chg tp
 chang prev ep
note tasli pharmaceut group co ltd china-bas compani mainli engag
manufactur distribut tradit chines medicin tcm product compani also
involv medic trade busi
click detail financi
manufactur pressur posit
tasli report quit strong result yoy revenu
growth yoy net profit growth oper cash flow improv
yoy gross margin improv pp higher
gross margin manufactur distribut segment sell
cost percentag sale increas pp penetr drug
sale aggress admin expens per sale remain stabl
financ cost increas due higher interest rate
sell sale
 sale
fin cost sale
manufactur segment sale increas gm improv
growth pu ke sale ramp yoy mn sale
includ nation drug reimburs list
tcm inject pressur contract
increas despit solid growth think
manufactur segment still face pressur go forward
figur manufactur busi grew yoy
distribut busi deliv yoy sale growth pp yoy
gross margin improv side account
receiv increas yoy due hospit delay payment
new normal distribut industri china otherwis
posit distribut busi due industri consolid
caus two invoic polici
updat drug
innov drug subsidiari own tasli
got cfda approv start phase clinic china
phase ii waiv china tasli licenc
first-in-class diabet drug got exclus china right
develop manufactur commercialis
china long-term finish clinic trial phase
maintain neutral increas tp
maintain neutral tasli given tcm inject draw
sale growth short term adjust ep forecast
slightli increas tp
factor rich pipelin drive long-term
growth tp base dcf model assum
wacc perpetu growth rate tasli rich pipelin
cover cardiovascular oncolog diabet therapi
support compani long-term growth view
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
compani mention price
serena shao certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
price rate histori co lli
signifi initi assumpt coverag
price rate histori tasli pharmaceut group co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european rate base stock total return
rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stock expect tot al return calcul
includ roll dividend yield outperform rate assign greater tha equal under-perform less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
